'No benefit' from hydroxychloroquine for Covid-19: major UK trial
[PARIS] A major British trial of hydroxychloroquine has found it has "no benefit" for patients hospitalised with Covid-19, researchers said Friday, announcing they had halted tests of the drug.
"We have concluded that there is no beneficial effect of hydroxychloroquine in patients hospitalised with Covid-19," said a statement from the chief investigators in the randomised clinical trial, which is run by the University of Oxford and is testing a number of potential treatments for the new coronavirus.
They added they would stop recruiting patients to the hydroxychloroquine part of the trial "with immediate effect".
AFP
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Possible class action lawsuit against Cordlife by customers could take at least 2 years
Chinese tariffs could leave cognac makers with too much brandy
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
WSJ moves Asia headquarters from Hong Kong to Singapore
South Korea to slap fines on food suppliers for ‘shrinkflation’
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share